The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer

Basit Öğe Kaydı
dc.authoridSahin, Taha Koray/0000-0002-3590-0426
dc.authorwosidSahin, Taha Koray/ABH-1748-2020
dc.contributor.authorGuven, Deniz Can
dc.contributor.authorSahin, Taha Koray
dc.contributor.authorKilickap, Saadettin
dc.date.accessioned2024-05-19T14:46:01Z
dc.date.available2024-05-19T14:46:01Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground: After the success of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC), the benefit of neoadjuvant chemoimmunotherapy was compared with chemotherapy for localized NSCLC in several trials. However, the available studies had variable study designs, and study cohorts had limited follow-up times. Therefore, we conducted a systematic review and meta-analysis to evaluate the benefit of adding immunotherapy to neoadjuvant chemotherapy in patients with localized NSCLC. Methods: We conducted a systematic review using Pubmed, Web of Science, and Scopus databases for studies published until 5 December 2023. This protocol was registered in the PROSPERO database (Registration Number: CRD42023466337). We performed the meta-analyses with the generic inverse-variance method with a fixed effects model. Results: Overall, 7 studies encompassing 2993 patients were included in the analyses. The use of neoadjuvant chemoimmunotherapy was associated with a 41% reduction in the risk of progression or death compared to neoadjuvant chemotherapy (HR: 0.59, 95% CI: 0.52-0.66, p < 0.0001) and a lower risk of death (HR: 0.67, 95% CI: 0.55-0.82, p < 0.0001). The neoadjuvant chemoimmunotherapy improved pCR rates compared to chemotherapy (21.8% vs. 3.8%, OR: 7.04, 95% CI: 5.23-9.47, p < 0.0001), while high-grade adverse events were higher with neoadjuvant chemoimmunotherapy (OR: 1.18, 95% CI: 1.02-1.36, p = 0.0300). Conclusions: The available evidence demonstrates a statistically significant and clinically meaningful event-free survival benefit and possibly an overall survival benefit with neoadjuvant chemoimmunotherapy with a slight increase in high-grade toxicities.en_US
dc.identifier.doi10.3390/cancers16010156
dc.identifier.issn2072-6694
dc.identifier.issue1en_US
dc.identifier.pmid38201583en_US
dc.identifier.scopus2-s2.0-85182246794en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org10.3390/cancers16010156
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5418
dc.identifier.volume16en_US
dc.identifier.wosWOS:001139752900001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofCancersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectNon-Small Cell Lung Cancer (Nsclc)en_US
dc.subjectEfficacy And Safetyen_US
dc.subjectImmune Checkpoint Inhibitors (Icis)en_US
dc.subjectNeoadjuvant Chemoimmunotherapyen_US
dc.subjectNeoadjuvant Immunotherapyen_US
dc.titleThe Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Canceren_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu